Sirolimus (SRL) inhibits the mammalian target of rapamycin, a cell proliferation protein kinase, resulting in inhibition of T-and B-cell activation.
1
SRL can cause seven distinct and uncommon pulmonary toxicities during SOT, including diffuse alveolar hemorrhage (DAH). 3 We report three cases of fatal lung toxicity in alloHCT patients receiving SRL.
Case 1, a 46-year-old woman, underwent HLA-matched unrelated alloHCT after BU/CY conditioning for chronic myeloid leukemia in 2003. She had no smoking or other significant medical history. She developed acute and chronic GVHD despite tacrolimus and MTX prophylaxis, and was treated with methylprednisolone and mycophenolate mofetil (MMF). At 1 year post-alloHCT, she developed obstructive lung disease and was started on fluticasone and salmeterol. At 3 years after BMT, she was started on dasatinib for bcr-abl positivity. Soon afterward, she developed dyspnea and bilateral pulmonary infiltrates. Bronchoalveolar lavage (BAL) culture showed a few colonies of Enterobacter cloacae, a probable contaminant; however, meropenem treatment was started. Her lung function did not improve and SRL treatment (0.2 mg orally) was started for presumed lung GVHD. Three days later she developed worsening dyspnea and airspace disease. A lung biopsy showed DAH with organizing pneumonia (Figure 1 ). She died of respiratory failure within 21 days after starting SRL.
Case 2, a 38-year-old woman, underwent HLA-matched sibling alloHCT after BU/CY conditioning for CLL in 2002. She had no smoking or other significant medical history. She developed acute and chronic GVHD, which was treated with tacrolimus, methylprednisolone, cyclosporine, plaquenil and extra-corporeal photopheresis. She developed tacrolimus-associated nephrotoxicity, and so SRL was started at 0.2 mg daily. SRL levels were 4.9-7.5 ng/dl for several weeks. She developed hypoxia, fever and renal failure. Owing to the presence of pulmonary infiltrates, medications including SRL were stopped because of possible drug toxicity. Her condition initially improved, but then she developed worsening bilateral air space disease; BAL and lung biopsy showed hemosiderin-laden macrophages, DAH and possible lung GVHD. She required hemodialysis and tacrolimus was stopped. SRL was re-initiated (0.2 mg orally daily) to treat presumed pulmonary GVHD. She developed disseminated intravascular coagulopathy and died of respiratory failure. Autopsy revealed severe DAH and acute lung injury (Figure 2 ). 
Case 3, a 41-year-old woman, underwent HLA-matched sibling alloHCT after BU/CY conditioning in 2007 for AML. Her past medical history included mild obstructive pulmonary disease and a 25 pack-year smoking history. She developed significant acute and chronic GVHD despite tacrolimus and MMF prophylaxis, and was treated with methylprednisolone, anti-thymocyte globulin, Etanercept and Rituximab without improvement. SRL (0.2 mg orally daily) was administered, but she developed hypoxia and extensive bilateral airspace disease. She had continued respiratory failure and died 7 days after SRL cessation. Autopsy revealed bronchopneumonia, alveolar membrane formation, fibrosis and hemorrhage.
HCT-associated DAH, a form of severe lung toxicity, occurs with dose-intensive therapy and the incidence ranges from 1 to 5% after autoHCT and from 3 to 7% after alloHCT. 4 Myeloablative conditioning and severe acute GVHD are independent risk factors for alloHCT DAH. 4 The median time post-alloHCT to the onset of DAH was lesser in an earlier report 4 (28 days, range 3-280) when compared with the corresponding values for the three patients in our case series (3.3, 5.1 and 0.4 years, respectively, post-alloHCT).
More than 70 cases of SRL-associated lung toxicity have been described in SOT patients. [5] [6] [7] [8] Usually it is reversible, with a 4.8% mortality rate. 8 High SRL levels (415 ng/dl), late drug exposure (that is, switch in therapy) and male gender are the risk factors. 8 The mechanism of SRLassociated pulmonary toxicity is not well understood. Etiologies include dose-dependent or immune-mediated toxicity, and direct drug toxicity. [8] [9] [10] Four diagnostic criteria have been proposed by Morelon et al. 9 for the diagnosis of SRL-associated lung toxicity: (1) SRL exposure before the onset of pulmonary symptoms; (2) exclusion of infection and other possible causal agents; (3) resolution of symptoms and radiological findings within 3 months after discontinuing or reducing SRL doses; and (4) lymphocytotoxic alveolar cell profile and pathological findings.
The common radiological findings related to DAH include bilateral, patchy infiltrates without mediastinal or pleural abnormalities. 4 Clinical suspicion of DAH and lung injury is usually confirmed by lung biopsy or autopsy. BAL will help exclude infectious etiologies. In SOT cases, respiratory support and SRL withdrawal usually lead to recovery.
The three patients in this report were receiving SRL at the onset of lung toxicity. They were immunosuppressed because of ongoing GVHD therapy. Lung injury due to infectious DAH was ruled out, owing to lack of antibiotic response and pathology results. Unfortunately, the presentations of lung toxicity were so severe and clinical deterioration so rapid that it was not possible to determine whether cessation of SRL would have led to an improved pulmonary status. Interestingly, all three cases involved women who received BU/CY conditioning. This is the first published series of three fatal cases of SRL-associated DAH in alloHCT recipients. SRL is widely used in SOT and recently in alloHCT. 2, 4 We recommend that SRL toxicity be considered in the differential diagnosis when pulmonary symptoms are manifested as DAH/hypoxia and lung infiltrates in alloHCT patients receiving SRL.
